News >

Lenalidomide/Rituximab Improves PFS in Phase III Indolent Lymphoma Study

Jason M. Broderick @jasoncology
Published: Tuesday, Jul 24, 2018

mcl
Combining lenalidomide (Revlimid) with rituximab (Rituxan) significantly improved progression-free survival (PFS) compared with rituximab alone for the treatment of patients with relapsed/refractory indolent lymphoma, meeting the primary endpoint of the phase III AUGMENT trial.

In results presented at the 2018 ASCO Annual Meeting, the R2 combination showed similar efficacy compared with rituximab plus chemotherapy, which failed to satisfy the primary endpoint for the phase III RELEVANCE trial for patients with untreated follicular lymphoma; however, the chemotherapy-free regimen had a more favorable safety profile, making it a potential first-line option.

After 120 weeks, R2 showed a complete remission (CR) or unconfirmed CR (CRu) rate of 48% compared with 53% for rituximab/chemotherapy (P = .13).1 The objective response rate (ORR) with the R2 regimen was 84% compared with 89% for rituximab/chemotherapy. The 3-year duration of response was 77% with R2 compared with 74% for rituximab/chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x